The neutropenia characterized by the accumulation of 1,5-AG-6 phosphate found in glycogen storage disease type 1, congenital neutropenia type 4 (associated with glucose-6-phosphate transporter deficiency and glucose-6-phosphatase catalytic subunit-3 deficiency), may respond to SGLT2 inhibitors [44,46]. This evidence concerns the gene SLC5A2 and hyperinsulinemic hypoglycemia, familial, 4.